Search results for " Osteonecrosis of the Jaw"

showing 10 items of 85 documents

Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology

2016

Introduction: Osteonecrosis of the jaw (ONJ) is a clinically important, potentially painful and debilitating condition, which can affect the quality of life of cancer patients. Since 2003, ONJ appeared as a Bisphosphonate(BP)-related class effect, and the term Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) was widespread. Areas Covered: Under discussion in this review is the fact that ONJ cases have been reported after treatment including antiangiogenic agents and other “targeted therapy”, with and without BPs. Consequently, the comprehensive term Medication-Related Osteonecrosis of the Jaw (MRONJ) has been introduced. The clinical aspects and the prognosis of ONJ associated with t…

aflibercept; bevacizumab; Bisphosphonate; Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ); denosumab; everolimus; Medication-Related Osteonecrosis of the Jaw (MRONJ); Osteonecrosis of the jaw (ONJ); sunitinib; temsirolimus; Angiogenesis Inhibitors; Antineoplastic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Humans; Jaw Diseases; Molecular Targeted Therapy; Neoplasms; Osteonecrosis; Quality of Life; Risk Assessment; Pharmacology (medical)Oncologysunitinibmedicine.medical_treatmentAngiogenesis InhibitorstemsirolimuTargeted therapyAntineoplastic Agent0302 clinical medicineNeoplasmsPharmacology (medical)Molecular Targeted TherapyJaw DiseaseafliberceptOsteonecrosisGeneral MedicineDenosumab030220 oncology & carcinogenesisOsteonecrosiBisphosphonate-Associated Osteonecrosis of the JawAngiogenesis InhibitorHumanmedicine.drugmedicine.medical_specialtyBevacizumabAntineoplastic AgentsbevacizumabRisk AssessmentBisphosphonate-Related Osteonecrosis of the Jaw (BRONJ)Medication-Related Osteonecrosis of the Jaw (MRONJ)03 medical and health sciencesInternal medicinemedicineBisphosphonateHumansBisphosphonate-associated osteonecrosis of the jawbusiness.industryeverolimuCancerdenosumab030206 dentistryBisphosphonatemedicine.diseaseOsteonecrosis of the jaw (ONJ)Quality of LifeNeoplasmJaw DiseasesOsteonecrosis of the jawbusinessJaw DiseasesExpert Opinion on Drug Safety
researchProduct

Medication-Related Osteonecrosis of Jaws (MRONJ) Prevention and Diagnosis: Italian Consensus Update 2020

2020

The Medication-Related Osteonecrosis of Jaws (MRONJ) diagnosis process and its prevention play a role of great and rising importance, not only on the Quality of Life (QoL) of patients, but also on the decision-making process by the majority of dentists and oral surgeons involved in MRONJ prevention (primary and secondary). The present paper reports the update of the conclusions from the Consensus Conference—held at the Symposium of the Italian Society of Oral Pathology and Medicine (SIPMO) (20 October 2018, Ancona, Italy)—after the newest recommendations (2020) on MRONJ were published by two scientific societies (Italian Societies of Maxillofacial Surgery and Oral Pathology and Medicine, SI…

bisphosphonateOral SurgeonHealth Toxicology and Mutagenesislcsh:MedicineMRONJantiangiogenic agents; antiresorptive drugs; bisphosphonates; cancer; denosumab; dentistry; MRONJ; oral surgery; osteoporosis; prevention models; bisphosphonate-associated osteonecrosis of the jaw; bone density conservation agents; diphosphonates; humans; Italy; quality of life0302 clinical medicineprevention modelCancerantiangiogenic agentsdentistryBone Density Conservation AgentsDiphosphonatesConference ReportBisphosphonatesAntiresorptive DrugsDenosumabItaly030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawDenosumabmedicine.drugoral surgerymedicine.medical_specialtyOral surgery03 medical and health sciencesOral surgeryAntiangiogenic agentsOral and maxillofacial pathologymedicinecancerHumansantiangiogenic agentantiresorptive drugsIntensive care medicinePrevention modelsbisphosphonatesantiresorptive drugAntiangiogenic agentsbusiness.industrylcsh:RPublic Health Environmental and Occupational Healthdenosumab030206 dentistrymedicine.diseaseosteoporosisAntiresorptive drugsDentistryOsteoporosisprevention modelsbusinessAntiangiogenic agents; Antiresorptive drugs; Bisphosphonates; Cancer; Denosumab; Dentistry; MRONJ; Oral surgery; Osteoporosis; Prevention models
researchProduct

CD34 and CD105 Microvessels in Resected Bone Specimen May Implicate Wound Healing in MRONJ

2021

Clinical treatment outcome of MRONJ (medication-related osteonecrosis of the jaw) surgery despite radical osseous removal and primary closure healing still shows differences in terms of outcome and disease recurrence. The study aims to assess the rate of angiogenesis of MRONJ lesions in order to understand the impact of angiogenesis and neoangiogenesis status on MRONJ surgical treatment outcome. This is the first study correlating microvessel density with prognosis in MRONJ surgically-treated patients. The immunohistochemical expression of CD34 and CD105 in MRONJ specimens obtained from surgically-treated patients was evaluated. The most vascularized areas detected by CD34 and CD105 were se…

medicine.medical_specialtyAngiogenesisHealth Toxicology and Mutagenesissurgical treatmentTreatment outcomeCD34MRONJArticleangiogenesismedicineHumansmedication-related osteonecrosis of the jawRadical surgeryRetrospective StudiesMicrovesselResected Bone SpecimenWound Healingbusiness.industryRPublic Health Environmental and Occupational HealthEndoglinmedicine.diseaseSurgeryCD105CohortMicrovesselstreatment outcomeMedicineBisphosphonate-Associated Osteonecrosis of the JawCD34Osteonecrosis of the jawWound healingbusinessInternational Journal of Environmental Research and Public Health
researchProduct

Review and update on drugs related to the development of osteonecrosis of the jaw

2019

Conflict of interest Conclusions of the working group on “New drugs related to the de-velopment of osteonecrosis of the jaw”. Spanish Society of Cranio-mandibular Dysfunction and Orofacial Pain and Spanish Society of Oral Medicine SEDCYDO-SEMO joint International Meeting: 30th SEDCYDO annual meeting & 15th SEMO Congress. Bilbao (Spain); June, 2019. [EN] Background: Medication-related osteonecrosis of the jaw (MRONJ) is a rare, but serious adverse effect of cer-tain drugs, of which bisphosphonates are the most widely known. This pathology is also associated with other medications such as the biologic antiresorptive agent, denosumab and some antiangiogenics such as sunitinib, bevacizumab or a…

medicine.medical_specialtyBevacizumabReviewMRONJ03 medical and health sciencesantiresorptives0302 clinical medicinemedicineHumansIntensive care medicineAdverse effectGeneral DentistrybisphosphonatesAfliberceptBisphosphonate-associated osteonecrosis of the jawOral Medicine and PathologyBone Density Conservation AgentsDiphosphonatesbusiness.industrySunitinibOsteonecrosis030206 dentistryEvidence-based medicinemedicine.disease:CIENCIAS MÉDICAS [UNESCO]osteonecrosis of the jawantiangiogenicsDenosumabOtorhinolaryngologyPharmaceutical PreparationsUNESCO::CIENCIAS MÉDICASSurgeryBisphosphonate-Associated Osteonecrosis of the JawDenosumabbusinessOsteonecrosis of the jawmedicine.drug
researchProduct

Current Controversies in Classification, Management, and Prevention of Bisphosphonate-Related Osteonecrosis of the Jaw

2014

Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a serious complication associated with oral and intravenous bisphosphonate therapy that adversely affects the quality of life, producing significant morbidity. Since the first description of bone necrosis in patients receiving bisphosphonate therapy in 2003 [1], hundreds of studies were published about this topic and various national and international medical societies have published protocols and guidelines. Nevertheless, there are still many controversies regarding the classification, management, and prevention of BRONJ. Even the definition of BRONJ is still debated and changed with the progress of knowledge and experience. Accord…

medicine.medical_specialtyBisphosphonate-associated osteonecrosis of the jawArticle Subjectbusiness.industrymedicine.medical_treatmentRetrospective cohort studyBisphosphonatemedicine.diseaseReview articleSurgeryBisphosphonate Osteonecrosis of the Jawlcsh:RK1-715EditorialDenosumablcsh:DentistryOral and maxillofacial pathologymedicineOral and maxillofacial surgeryIntensive care medicineOsteonecrosis of the jawbusinessGeneral Dentistrymedicine.drugInternational Journal of Dentistry
researchProduct

Comment on Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline Summary

2020

medicine.medical_specialtyBisphosphonate-associated osteonecrosis of the jawOncology (nursing)business.industryHealth PolicyMEDLINEGuidelinemedicine.diseaseClinical PracticeOncologymascc isoo ascoo mrojHumansMedicineBisphosphonate-Associated Osteonecrosis of the JawbusinessOsteonecrosis of the jawIntensive care medicineJCO Oncology Practice
researchProduct

The Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review with a Pooled Analysis of Only Surgery versus Combined Prot…

2021

Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse reaction of antiresorptive and antiangiogenic agents, and it is also a potentially painful and debilitating condition. To date, no specific studies have prospectively evaluated the efficacy of its treatment and no robust standard of care has been established. Therefore, a systematic review (2007–2020) with a pooled analysis was performed in order to compare MRONJ surgical techniques (conservative or aggressive) versus combined surgical procedures (surgery plus a non-invasive procedure), where 1137 patients were included in the pooled analysis. A statistically significant difference in the 6-month improvement rate, comp…

medicine.medical_specialtyHealth Toxicology and Mutagenesismedicine.medical_treatmentONJReviewsurgerymedicineHumansAdverse effectONJ Osteonecrosis Staging Surgery Therapy TreatmenttherapyONJ; Osteonecrosis; Staging; Surgery; Therapy; Treatment; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Humans; Bone Density Conservation AgentsDiphosphonatesBone Density Conservation Agentstreatmentbusiness.industryosteonecrosisSignificant differenceBlood componentRPublic Health Environmental and Occupational HealthstagingSurgical proceduresmedicine.diseaseSurgeryPooled analysisImprovement rateMedicineBisphosphonate-Associated Osteonecrosis of the JawOsteonecrosis of the jawbusinessAdjuvantInternational Journal of Environmental Research and Public Health
researchProduct

Spontaneous bisphosphonate-related osteonecrosis of the left hemi-mandible: Similarities with phossy jaw.

2013

Intravenous bisphosphonates (BP) play a key role in the treatment of bone metastases. As a long-term side effects BP, a form of avascular osteonecrosis of the jaw has been reported. Although, invasive oral local procedures are often present in clinical history of patients suffering from bisphosphonates-related osteonecrosis of the jaws (BRONJ), about up to 50% of BRONJ are spontaneous. We report a case of a 68-year-old female with a spontaneous wide bone sequestration of the left mandibular body onset after infusion of zoledronic acid for 18 cycles for osseous metastasis due to metastatic anaplastic thyroidal carcinoma. Surprisingly the clinical aspects of the patient initially reminded us …

medicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentBone NeoplasmsZoledronic AcidBone sequestrationstomatognathic systemMandibular bodySettore MED/28 - Malattie OdontostomatologichemedicineCarcinomaHumansMandibular DiseasesThyroid Neoplasmsthyroidal carcinomaGeneral DentistryAgedPhossy jawBone Density Conservation AgentsDiphosphonatesbusiness.industryCarcinomaMandibleImidazolesBisphosphonatesGeneral MedicineBisphosphonatemedicine.diseaseBisphosphonatesbisphosphonates‑related osteonecrosis of the jaws thyroidal carcinoma zoledronic acidbisphosphonates-related osteonecrosis of the jawsSurgerylcsh:RK1-715stomatognathic diseasesZoledronic acidlcsh:DentistryBisphosphonate-Associated Osteonecrosis of the JawFemaleOsteonecrosis of the jawbusinessmedicine.drugFollow-Up Studies
researchProduct

Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents

2015

Background The clinical management of medication-related osteonecrosis of the jaw (MRONJ) in patients treated with bisphosphonates and other antiresorptive agents is subject to controversy. The American Association of Oral and Maxillofacial Surgeons (AAOMS) has developed guidelines for the correct management of the disorder which are revised and updated by a panel of experts. Material and Methods The present systematic review analyzes the different treatments currently used to treat this clinical condition, based on the PRISMA® (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement published in 2009. An electronic Medline search was made of the PubMed database, cover…

medicine.medical_specialtyMEDLINEAlternative medicineDentistryDiseaseReview03 medical and health sciences0302 clinical medicineAntiresorptive AgentsmedicineHumansStage (cooking)Intensive care medicineGeneral DentistryBisphosphonate-associated osteonecrosis of the jawBone Density Conservation AgentsDiphosphonatesbusiness.industryOsteonecrosis030206 dentistrymedicine.diseaseMedically compromised patients in Dentistry:CIENCIAS MÉDICAS [UNESCO]Systematic reviewOtorhinolaryngology030220 oncology & carcinogenesisTooth ExtractionUNESCO::CIENCIAS MÉDICASSurgeryBisphosphonate-Associated Osteonecrosis of the JawbusinessOsteonecrosis of the jaw
researchProduct

Learning from experience. Proposal of a refined definition and staging system for bisphosphonate-related osteonecrosis of the jaw (BRONJ)

2012

Dear Editor, It is the authors’ belief that the internationally accepted definition of bisphosphonate-related osteonecrosis of the jaws (BRONJ) (Ruggiero et al, 2009) has several limitations that prevent clinicians from being confident with the diagnosis of the disease. Following recognition of the non-exposed BRONJ clinical variant (Lazarovici et al, 2009), we all became aware that the presence of ‘exposed necrotic bone in the oral cavity’, as outlined in the American Association of Oral and Maxillofacial Surgery (AAOMS) case definition, is just one of the possible clinical manifestations of BRONJ and is not found in all BRONJ patients. As ‘bone exposure’ is certainly not the initial sign …

medicine.medical_specialtyMedullary cavityBone diseaseBiopsymedicine.medical_treatmentSettore MED/29 - Chirurgia MaxillofaccialeDiagnosis DifferentialSettore MED/28 - Malattie OdontostomatologicheTerminology as TopicOral and maxillofacial pathologymedicineHumansGeneral DentistryBisphosphonate-associated osteonecrosis of the jawBone Density Conservation AgentsDiphosphonatesbusiness.industryDecision TreesBisphosphonatemedicine.diseaseSurgeryOtorhinolaryngologybisphosphonate-related osteonecrosis of the jawOral and maxillofacial surgeryBisphosphonate-Associated Osteonecrosis of the JawDifferential diagnosisOsteonecrosis of the jawbusiness
researchProduct